Lantern Pharma has dosed two subjects in a Phase Ia/Ib clinical trial of its investigational drug LP-284 for relapsed or refractory non-Hodgkin’s lymphoma (NHL).
A new small molecule, LP-284 has a synthetically lethal mechanism of action that kills cancer cells harbouring mutations in DNA damage repair pathways.
The multicentre, open-label trial aims to determine the safety and tolerability of varying doses of the molecule.
LP-284 will be assessed for its potential to treat mantle cell lymphoma (MCL), double hit lymphoma (DHL), high-grade B-cell lymphomas (HGBL), and selected solid tumours and sarcomas.
The trial will also investigate the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) in patients with relapsed or refractory (r/r) lymphomas and solid tumours.
Characterising the pharmacokinetics (PK) of LP-284 and evaluating its clinical activity are the trial’s secondary objectives.
https://www.clinicaltrialsarena.com/news/lantern-non-hodgkins-lymphoma-trial/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.